PUBLIC COMPANY
saveInSilico Medicine
updated 5mo ago
community read0 votes
pipeline
4
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
1Preclinical2Phase 11Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Menarini's Stemline picks up Georgiamune preclinical cancer immunotherapy in $1.1B dealGeorgiamune, an immunology-focused biotech out of Maryland, has licensed a preclinical cancer drug candidate to Stemline Therapeutics, owned by Italy's Menarini Group, for up to $1.1 billion.fiercebiotech · 26d ago
- Lilly partners with Hong Kong's Metis in $1.1B deal to bolster AI nanoparticle discoveryThe collaboration is another in a series of partnerships Lilly has accumulated in both drug delivery and AI-based technologies.fiercebiotech · 29d ago
- Cerevance Parkinson’s drug shortens 'off time' in Ph. 3, paving path to FDAThe Takeda spinout showed that a high dose of solengepras can shorten the periods during which difficult Parkinson’s disease symptoms like involuntary movements and sleepiness.biospace · 1mo ago
- Lilly’s latest China drug deal; Immunovant’s setback in lupusLilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded a…biopharma_dive · 1mo ago
- Deep Dive: How AI is now essential in biopharmaAs Big Pharma adds AI technology to bolster drug development, a cadre of new, upstart biotechs are pushing drug discovery to new heights.biospace · 1mo ago
- Novo looks to Anthropic’s AI models to ‘supercharge’ drug developmentThe Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company."biopharma_dive · 2mo ago
- Owkin, Servier ink oncology R&D deal to guide discovery and trial designAI drug discovery company Owkin has signed a pact with French drugmaker Servier to license Owkin’s AI scientist K Pro across Servier’s oncology discovery and trial operations.fiercebiotech · 2mo ago
- Reeling from past failures, Parkinson's pipeline enters 'era of diversification'While some drugmakers continue to walk the alpha-synuclein antibody path, others like AC Immune opt for new approaches that could bring the first-ever disease-modifying therapy for Parkinson's dise…biospace · 2mo ago
- China poses increasing security risk as US biotech innovation edge erodesThe U.S. is scrambling to compete with a strategically positioned China on the biotech stage as the Asian country surpasses America in biomedical research and clinical trials. So far, China is winn…biospace · 2mo ago
- Research into protein interactions sheds new light on causes of autismStudying protein-protein interactions might hold the key to identifying druggable targets for autism, a group of scientists at the University of California, San Francisco has suggested.fiercebiotech · 2mo ago
comments(0)
5-min edit window · permanent after that